阿卡迪亚 2026年季度报告

FORM 10-Q ☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIESEXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2026 TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIESEXCHANGE ACT OF 1934 Commission File Number: 000-50768 ACADIA PHARMACEUTICALS INC. (Exact Name of Registrant as Specified in Its Charter) Delaware(State of Incorporation) 06-1376651(I.R.S. Employer Identification No.) 12830 El Camino Real, Suite 400San Diego, California(Address of Principal Executive Offices) 92130(Zip Code) (858) 558-2871(Registrant’s Telephone Number, Including Area Code) Securities registered pursuant to Section 12(b) of the Act: Title of Each ClassTrading SymbolName of Each Exchange on Which RegisteredCommon Stock, par value $0.0001 per shareACADThe Nasdaq Stock Market LLC Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of theSecurities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to filesuch reports), and (2) has been subject to such filing requirements for the past 90 days.Yes☒No☐ Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to besubmitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorterperiod that the registrant was required to submit such files).Yes☒No☐ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smallerreporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smallerreporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act. Large accelerated filer☒Non-accelerated filer☐Emerging growth company☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition periodfor complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.☐ Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).Yes☐No☒ Total shares of registrant’s common stock outstanding as of the close of business on April 29, 2026: ACADIA PHARMACEUTICALS INC.FORM 10-QTABLE OF CONTENTS PART I. FINANCIAL INFORMATION Item 1.Financial Statements1Condensed Consolidated Balance Sheets1Condensed Consolidated Statements of Operations2Condensed Consolidated Statements of Comprehensive Income3Condensed Consolidated Statements of Cash Flows4Condensed Consolidated Statements of Stockholders’ Equity5Notes to Condensed Consolidated Financial Statements6Item 2.Management’s Discussion and Analysis of Financial Condition and Results of Operations18Item 3.Quantitative and Qualitative Disclosures About Market Risk24Item 4.Controls and Procedures25PART II. OTHER INFORMATIONItem 1.Legal Proceedings26Item 1A.Risk Factors26Item 5.Other Information63Item 6.Exhibits64SIGNATURES65 ACADIA PHARMACEUTICALS INC.CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS(in thousands, except per share amounts)(Unaudited) ACADIA PHARMACEUTICALS INC.CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME(in thousands)(Unaudited) The accompanying notes are an integral part of these unaudited condensed consolidated financial statements. ACADIA PHARMACEUTICALS INC.CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS(in thousands)(Unaudited) ACADIA PHARMACEUTICALS INC.CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY(in thousands)(Unaudited) ACADIA PHARMACEUTICALS INC.NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS(Unaudited) 1. Organization and Business Acadia Pharmaceuticals Inc. (the Company), based in San Diego, California, is a biopharmaceutical company focused onturning scientific promise into meaningful innovation that makes the difference for underserved neurological and rare diseasecommunities around the world. In April 2016, the U.S. Food and Drug Administration (FDA) approved the Company’s first drug, NUPLAZID®(pimavanserin), for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis (PDP). NUPLAZIDbecame available for prescription in the United States in May 2016. In March 2023, the FDA approved the Company’s second drug, DAYBUE®(trofinetide), for the treatment of Rett syndrome.DAYBUE became available for prescription in the United States in April 2023. In October 2024, Health Canada granted marketing authorization of DAYBUE®(trofinetide) for the treatment of Rettsyndrome in adult and pediatric patients 2 years of age and older. In December 2025, the FDA approved DAYBUE®STIX (trofinetide), a dye- and preservative-free powder formulation, forthe treatment of Rett syndrome in adult and pediatric patients 2 years and older. DAYBUE STIX was available on a limited basisstarting